Power Law company profile

Ardelyx

Biotech & Life Sciences · Fremont, United States · Founded 2007 · IPO 2014 Unicorn

Develops novel oral therapeutics to treat mineral metabolism and metabolic disorders

Valuation

$1.51B

Market cap · May/2026

Revenue

$378M

Latest reported FY

EBITDA

$33M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

4 investors on Ardelyx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

NEA

CMEA Capital

Series B+ 2 investors entered at this stage

Amgen Ventures

Amgenbd

Global footprint

Where Ardelyx has talent and traffic

AI talent share

0.2% of workforce is AI talent
(1 of 485 staff)

Core AI00%

Other AI10.21%

Non-AI workforce48499.79%

Workforce by country

2 countries with
team presence

🇺🇸 United States99.4%

🏳️ Liechtenstein0.3%

2 countries shown

Web traffic by country

12K monthly visits
across markets

🇺🇸 United States88.3%

🇮🇳 India14.2%

🇨🇦 Canada1.7%

Top 3 markets shown

Market sentiment

What the market is saying about Ardelyx

An AI-synthesized read of the highest-engagement posts about Ardelyx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ardelyx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles